|  |  |  |  |
| --- | --- | --- | --- |
| Segment ID | Segment status | Source segment | Target segment |
| 10e6754d7-a3db-40ad-a9ad-e0c297e61fa9 | Translated (CM) | OrderInformation (Immuno Reagents) + Sum | Užsakymo Informacija (Imunologiniai reagentai) + Santr |
| 20499a0e2-0125-4d49-a5aa-13d6f98684d7 | Translated (100%) | <34>11820796</34> 190 | <34>11820796</34> 190 |
| 305b5e023-fd62-4d4f-8614-afbb370fd09b | Translated (99%) | 100 | 100 |
| 4ec3ae39c-6e4e-4c7a-ae7b-f355311c1d65 | Translated (CM) | Elecsys 2010 | Elecsys 2010 |
| 58c819a37-f7cb-4fcf-9018-bd3e52e3c874 | Translated (CM) | MODULAR ANALYTICS E170 | MODULAR ANALYTICS E170 |
| 69c67986d-0a80-4774-951c-a4d7d292bce1 | Translated (CM) | <48>cobas e</48> 411 | <48>cobas e</48> 411 |
| 75618743f-dda6-4971-8b5f-4283b5ea36bf | Translated (CM) | <51>cobas e</51> 601 | <51>cobas e</51> 601 |
| 8b24d6cca-76b9-41f9-af6c-a3e81701c53f | Translated (CM) | <54>cobas e</54> 602 | <54>cobas e</54> 602 |
| 9cf0863af-1a50-41d8-8417-915a2c75746d | Translated (CM) | Intended use | Paskirtis |
| 10f5bef06b-9cf8-4e2e-89b7-59f0a3fecd7c | Translated (96%) | Immunoassay for the in vitro quantitative determination of digoxin in human serum and plasma. | Imunologinis kiekybinis in vitro tyrimas, skirtas digoksino koncentracijos nustatymui žmogaus serume ir plazmoje. |
| 11f5bef06b-9cf8-4e2e-89b7-59f0a3fecd7c | Translated (0%) | Measurements are used in the diagnosis and treatment of digoxin overdose and in monitoring levels of digoxin to ensure proper therapy. | Tyrimai yra naudojami digoksino perdozavimo diagnostikai ir gydymui bei digoksino koncentracijos stebėsenai siekiant optimalaus gydymo. |
| 121a8635a4-61a7-4ab8-b2e4-92e88857d775 | Translated (100%) | Summary | Santrauka |
| 13b0502bcf-4eb7-4001-bca8-de28414cafd1 | Translated (0%) | Digoxin is a widely prescribed steroidal cardio-active glycoside. | Digoksinas yra dažnai skiriamas širdį veikiantis glikozidas. |
| 14b0502bcf-4eb7-4001-bca8-de28414cafd1 | Translated (0%) | It acts by binding and inhibiting the Na<99>+</99>/K<100>+</100>-ATPase which in the end increases the intracellular Ca<101>2+</101> concentration.<Hauptmann PJ, Kelly RA Digitalis. Circulation 1999;99:1265-1270./><103>,</103><Katz A, Lifshitz Y, Bab-Dinitz E, et al. Selectivity of Digitalis Glycosides for Isoforms of Human Na,K-ATPase. J Biol Chem 2010 Jun;285(25) 19582-19592./> This results in a positive inotrope effect which makes digoxin a beneficial drug for heart failure. | Jis veikia prisijungdamas ir slopindamas Na<99>+</99>/K<100>+</100>-ATPazę, kuri padidina viduląstelinę Ca<101>2+</101> koncentraciją.<Hauptmann PJ, Kelly RA Digitalis. Circulation 1999;99:1265-1270./><103>,</103><Katz A, Lifshitz Y, Bab-Dinitz E, et al. Selectivity of Digitalis Glycosides for Isoforms of Human Na,K-ATPase. J Biol Chem 2010 Jun;285(25) 19582-19592./> Tai sukelia teigiamą inotropinį poveikį, kuris yra naudingas sergant širdies nepakankamumu. |
| 15b0502bcf-4eb7-4001-bca8-de28414cafd1 | Translated (0%) | It improves the strength of myocardial contraction and results in the beneficial effects of increased cardiac output, increased Left Ventricular Ejection Fraction, and decreased Pulmonary Capillary Wedge pressure.<Eichhorn EJ, Gheorghiade M Digoxin. Progress Cardiovasc Diseases 2002 Jan/Feb;44(4):251-266./><106>,</106><Gheorghiade M, van Veldhuisen DJ, Colucci WS. Contemporary Use of Digoxin in the Management of Cardiovascular Disorders. Circulation 2006;113:2556-2564./> Digoxin therapy also results in stabilized and slowed ventricular pulse rate. | Jis didina miokardo susitraukimo jėgą ir nulemia sistolinio tūrio bei širdies išmetimo frakcijos padidėjimą ir sumažėjusį plaučių kapiliarų pleištinį slėgį.<Eichhorn EJ, Gheorghiade M Digoxin. Progress Cardiovasc Diseases 2002 Jan/Feb;44(4):251-266./><106>,</106><Gheorghiade M, van Veldhuisen DJ, Colucci WS. Contemporary Use of Digoxin in the Management of Cardiovascular Disorders. Circulation 2006;113:2556-2564./> Gydymas digoksinu taip pat stabilizuoja ir lėtina skilvelių susitraukimo dažnį. |
| 165c45047f-86bd-4ed7-8237-00cad5bb650f | Translated (0%) | Although the availability of crystalline digoxin has permitted the standardization of drug dosage, therapeutic administration inadvertently, yet frequently, results in toxicity. | Nors kristalinio digoksino prieinamumas leido standartizuoti dozavimą, gydymas juo netyčia, tačiau dažnai, pasižymi toksiškumu. |
| 175c45047f-86bd-4ed7-8237-00cad5bb650f | Translated (0%) | Importantly, symptoms of digoxin toxicity often mimic the cardiac arrhythmias for which the drug was originally prescribed. | Svarbu tai, kad digoksino toksinio poveikio simptomai dažnai panašūs į širdies aritmijos simptomus, dėl kurių ir skiriamas vaistas. |
| 185c45047f-86bd-4ed7-8237-00cad5bb650f | Translated (0%) | Digoxin concentrations of 0.9<111/>2.0 ng/mL in serum or plasma are normally considered to be therapeutic.<Oellerich M. Pharmaka (Drug monitoring). In: Thomas L (ed.). Labor und Diagnose, TH-Books, Frankfurt, 5. edition, 1998:1174. Englisch: Clinical Laboratory. 1st English Edition 1998:1151./><113>,</113><Jortani SA, Valdes R Jr. Digoxin and Its Related Endogenous Factors. Critical Reviews Clin Lab Sci 1997;34(3):225-274./> However, later studies observed an increased risk for mortality for digoxin concentrations of 1.2 ng/mL and higher.<Rathore SS, Curtis JP, Wang Y, et al. Association of Serum Digoxin Concentration and Outcome in Patients with Heart Failure. JAMA 2003 Feb;289(7):871-878./><116>,</116><Adams KF, Patterson JH, Gattis WA, et al. Relationship of Serum Digoxin Concentration to Mortality and Morbidity in Women in the Digitalis Investigation Group Trail. J Am Coll Cardiology 2005;46(3):497-504./> These observations are also reflected in the “ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008” which recommend a therapeutic concentration range for digoxin of 0.6<118/>1.2 ng/mL<Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-2442./> and other guidelines even recommend limits < 1.0 ng/mL. | Digoksino koncentracija serume ar plazmoje 0.9<111/>2.0 ng/mL ribose įprastai laikoma terapine.<Oellerich M. Pharmaka (Drug monitoring). In: Thomas L (ed.). Labor und Diagnose, TH-Books, Frankfurt, 5. edition, 1998:1174. Englisch: Clinical Laboratory. 1st English Edition 1998:1151./><113>,</113><Jortani SA, Valdes R Jr. Digoxin and Its Related Endogenous Factors. Critical Reviews Clin Lab Sci 1997;34(3):225-274./> Tačiau vėliau atliktų tyrimų metu didesnė mirtingumo rizika buvo stebėta digoksino koncentracijai esant 1.2 ng/mL ir daugiau.<Rathore SS, Curtis JP, Wang Y, et al. Association of Serum Digoxin Concentration and Outcome in Patients with Heart Failure. JAMA 2003 Feb;289(7):871-878./><116>,</116><Adams KF, Patterson JH, Gattis WA, et al. Relationship of Serum Digoxin Concentration to Mortality and Morbidity in Women in the Digitalis Investigation Group Trail. J Am Coll Cardiology 2005;46(3):497-504./> Šie pastebėjimai taip pat atsispindi ir “ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008” (liet. "EKD 2008 metų ūminio ir lėtinio širdies nepakankamumo diagnostikos ir gydymo gairės"), kuriose rekomenduojamas 0.6<118/>1.2 ng/mL digoksino terapinis intervalas<Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-2442./>, o kitose gairėse rekomenduojama netgi < 1.0 ng/mL riba. |
| 194ef1e4c5-9b75-4b5e-b745-a52f22f2ab4c | Translated (0%) | Toxicity of digoxin may reflect several factors: | Digoksino toksiškumas gali būti nulemtas kelių veiksnių: |
| 2002e0ba47-290d-43ff-aba5-9348b4d58ddd | Translated (0%) | The drug has a low therapeutic ratio (i.e. a very small difference exists between therapeutic and toxic tissue levels); | Vaistas pasižymi mažu terapiniu santykiu (t.y. labai mažas skirtumas tarp terapinės ir toksinės koncentracijos audiniuose); |
| 2107315350-c834-484b-b154-5037a94f9cbf | Translated (0%) | Individuals vary in their response to digoxin; | Skirtingi individai pasižymi skirtingu atsaku į digoksiną; |
| 2269ebe795-879e-47f5-91ef-3a7802767993 | Translated (0%) | Absorption of various tablet forms of digoxin may vary over a two-fold range;<Lindenbaum J, Mellow MH, Blackstone MO, et al. Variation in Biologic Availability of Digoxin from Four Preparations. New Engl J Med 1971;285:1344-1347./><137>,</137> | Skirtingų digoksino tablečių formų absorbcija gali skirtis iki dviejų kartų;<Lindenbaum J, Mellow MH, Blackstone MO, et al. Variation in Biologic Availability of Digoxin from Four Preparations. New Engl J Med 1971;285:1344-1347./><137>,</137> |
| 23e27bc815-baf9-4c39-9042-80d488a24e4a | Translated (0%) | Susceptibility to digitalis toxicity apparently increases with age mainly associated with renal impairment. | Digitalio toksiškumo rizika didėja su amžiumi, o tai daugiausiai siejama su trinkančia inkstų veikla. |
| 24b61b98c2-6b14-482c-8cf9-21f4a4f39724 | Translated (81%) | In combination with other clinical data, monitoring serum or plasma levels may provide the physician with useful information to aid in adjusting patient dosage, and achieving optimal therapeutic effect, while avoiding both subtherapeutic and harmful toxic drug levels. | Kartu su klinikiniais duomenimis, digoksino koncentracijos serume ar plazmoje stebėsena gali suteikti vertingos informacijos, skirtos paciento dozės koregavimui, siekiant optimalaus vaisto poveikio ir išvengiant subterapinės koncentracijos ar vaisto toksiškumo. |
| 255a7364dc-6373-4230-bac3-dc74a3471f18 | Translated (80%) | The Elecsys Digoxin assay employs a competitive test principle using a monoclonal antibody specifically directed against digoxin. | Elecsys Digoxin tyrimo pagrindas - konkurencinis tyrimo principas, naudojant antikūnus, kurie specifiškai nukreipti prieš digoksiną. |
| 265a7364dc-6373-4230-bac3-dc74a3471f18 | Translated (80%) | Digoxin in the sample competes with the added digoxin derivative labeled with biotin for the binding sites on the ruthenylated antibody-complex<152>Tris(2,2'-bipyridyl)ruthenium(II)-complex (Ru(bpy)<153/>)</152>. | Mėginyje esantis digoksinas konkuruoja su pridėtu digoksino derivatu, žymėtu biotinu, dėl prisijungimo vietos ant rutenilinto antikūno komplekso<152>Tri(2,2'-bipyridil)rutenio(II)-kompleksas(Ru(bpy)<153/>)</152>). |
| 275fa0a94e-e06e-49f9-be8b-0983f71cf890 | Translated (100%) | Test principle | Tyrimo principas |
| 28e9b98d7b-f15b-4307-b47c-5a60d13b3bae | Translated (CM) | Competition principle. | Konkurencijos principas. |
| 29e9b98d7b-f15b-4307-b47c-5a60d13b3bae | Translated (CM) | Total duration of assay: | Bendra tyrimo trukmė: |
| 30e9b98d7b-f15b-4307-b47c-5a60d13b3bae | Translated (CM) | 18 minutes. | 18 minučių. |
| 315d37764d-55f1-4e86-8939-f8abb19e560e | Translated (CM) | 1st incubation: | 1-oji inkubacija: |
| 325d37764d-55f1-4e86-8939-f8abb19e560e | Translated (94%) | By incubating the sample (10 µL) with a digoxin<170/>specific ruthenium-labeled antibody, an immunocomplex is formed, the amount of which is dependent upon the analyte concentration in the sample. | Inkubuojant mėginį (10 µL) su digoksinui<170/>specifišku ruteniu žymėtu antikūnu, susidaro imuninis kompleksas, kurio kiekis priklauso nuo analitės koncentracijos mėginyje. |
| 333138b3f7-f3c7-4677-9a1a-040ab33458e6 | Translated (100%) | 2nd incubation: | 2-oji inkubacija: |
| 343138b3f7-f3c7-4677-9a1a-040ab33458e6 | Translated (79%) | After addition of streptavidin-coated microparticles and a digoxin derivative labeled with biotin, the still-vacant sites of the ruthenium labeled antibodies become occupied, with formation of an antibody-hapten complex. | Pridėjus streptavidinu padengtų mikrodalelių ir digoksino derivato, pažymėto rutenio kompleksu, užimamos vis dar laisvos ruteniu žymėtojo antikūno sujungiančiosios sritys, susidarant antikūno-hapteno kompleksui. |
| 353138b3f7-f3c7-4677-9a1a-040ab33458e6 | Translated (100%) | The entire complex becomes bound to the solid phase via interaction of biotin and streptavidin. | Sąveikaujant biotinui ir streptavidinui visas kompleksas prijungiamas prie kietosios fazės. |
| 368aac644a-94dc-4a21-8f85-2282d4030f6b | Translated (99%) | Reagents - working solutions | Reagentai - darbiniai tirpalai |
| 3766507cc0-3fc5-4633-ab7e-7eb7a6a630ae | Translated (91%) | The reagent rackpack is labeled as DIGO. | Ši reagentų stovo pakuotė yra pavadinta DIGO. |
| 38115ff089-68db-4d28-95b6-59f9a884ddd5 | Translated (100%) | M | M |
| 395019002c-f72a-4081-a3bd-d78847605ce2 | Translated (CM) | Streptavidin-coated microparticles (transparent cap), 1 bottle, 6.5 mL: | Streptavidinu dengtos mikrodalelės (permatomas dangtelis), 1 buteliukas, 6.5 mL: |
| 4063ae8722-5d56-443f-8531-57ed692f2c98 | Translated (CM) | Streptavidin-coated microparticles 0.72 mg/mL; preservative. | Streptavidinu dengtos mikrodalelės, 0.72 mg/mL; konservantas. |
| 411dc9f42a-3c65-42d0-bdf5-26bba85902ac | Translated (CM) | R1 | R1 |
| 42751bdeb7-c2f3-4529-a368-bee4c69d52bf | Translated (0%) | Anti-digoxin-Ab~Ru(bpy)<225/> (gray cap), 1 bottle, 10 mL: | Anti-digoksino-Ak~Ru(bpy)<225/> (pilkas dangtelis), 1 buteliukas, 10 mL: |
| 43cf623a8c-3cbd-4dff-9326-340c37b40e3d | Translated (93%) | Monoclonal anti-digoxin antibody (mouse) labeled with ruthenium complex 15 µg/L; phosphate buffer 100 mmol/L, pH 7.0; preservative. | Monokloniniai anti-digoksino antikūnai (pelės), žymėti rutenio kompleksu 15 µg/L; fosfato buferis 100 mmol/L, pH 7.0; konservantas. |
| 449b3108c3-c9af-4282-af46-62aa2b8bb378 | Translated (100%) | R2 | R2 |
| 458d6c3025-5287-4c37-b68b-e1aba8bb719b | Translated (0%) | Digoxin-derivative~biotin (black cap), 1 bottle, 10 mL: | Digoksino-derivatas~biotinas (juodas dangtelis), 1 buteliukas, 10 mL: |
| 4677409e60-f756-4927-8747-73e712d76248 | Translated (82%) | Biotinylated digoxigenin 1.06 ng/mL; biotin 15 µg/L; phosphate buffer 100 mmol/L, pH 7.0; preservative. | Biotinilintas digoksigeninas 1.06 ng/mL; biotinas 15 µg/L; fosfato buferis 100 mmol/L, pH 7.0; konservantas. |
| 47c7c8d6eb-6a94-4ed3-9746-2d9d66750a89 | Translated (100%) | Precautions and warnings | Atsargumo priemonės ir įspėjimai |
| 487368a8f7-e745-43a2-af45-b1b3a89b48f0 | Translated (99%) | Reagent handling | Reagentų paruošimas |
| 49d0a3db80-fb45-4156-933c-09c6fde3d0b5 | Translated (CM) | Storage and stability | Laikymo sąlygos ir stabilumas |
| 507d0d57e2-5762-4d59-afd1-0db47d4cf4c8 | Translated (CM) | Stability: | Stabilumas: |
| 5148ff8ee7-21b7-4c0d-a423-b10efa16528b | Translated (CM) | unopened at 2<339/>8 °C | neatidarius, 2<339/>8 °C temperatūroje |
| 523472208a-2aae-4210-8168-38e8715b2945 | Translated (CM) | up to the stated expiration date | iki nurodytos galiojimo datos |
| 538405161b-4fe6-4db2-94a7-167c9ef41808 | Translated (CM) | after opening at 2<350/>8 °C | atidarius, 2<350/>8 °C temperatūroje |
| 54aa6377d2-e687-4d51-899f-58abbf71f1ad | Translated (CM) | 12 weeks | 12 savaičių |
| 554b6d9572-2435-4e42-b9ed-c517298d8c4b | Translated (CM) | on the analyzers | analizatoriuose |
| 569a0fb21a-d22a-45d9-8c9f-1ef3d0a23fd2 | Translated (CM) | 8 weeks | 8 savaitės |
| 57e32759db-4046-472d-9f1a-a47632d742f5 | Translated (CM) | Specimen collection and preparation | Mėginių surinkimas ir paruošimas |
| 58aae34316-892c-4e9e-a544-23859566c918 | Translated (0%) | Blood samples for digoxin analyses should be collected at trough levels which is just prior to the next drug dose or at least 12 hours, and preferably 24 hours after the previous digoxin dose. | Digoksino tyrimams skirti kraujo mėginiai turėtų būti surenkami iškart prieš kitą vaisto dozės suvartojimą (angl. trough) arba mažiausiai 12, o geriausia praėjus 24 valandoms po paskutinės digoksino dozės suvartojimo. |
| 59aae34316-892c-4e9e-a544-23859566c918 | Translated (0%) | Considering a blood elimination half-life of 1.5 days for digoxin, steady state blood concentrations require approximately 1 week after initiation of therapy – or longer in case of abnormal kidney function. | Atsižvelgiant į tai, kad digoksino eliminavimo iš kraujotakos pusperiodis yra 1.5 dienos, stabili koncentracija kraujyje pasiekiama apytiksliai per 1 savaitę nuo gydymo pradžios - arba vėliau, esant inkstų funkcijos sutrikimams. |
| 60ba23976e-7d45-40e5-a93a-2b034d0161d5 | Translated (0%) | Li-heparin, K<397>2</397><398/>EDTA and K<399>3</399><400/>EDTA plasma. | Li-heparino, K<397>2</397><398/>EDTA ir K<399>3</399><400/>EDTA plazma. |
| 61ba23976e-7d45-40e5-a93a-2b034d0161d5 | Translated (100%) | Li<401/>heparin plasma tubes containing separating gel can be used. | Gali būti naudojami Li<401/>heparino mėgintuvėliai su skiriančiuoju geliu. |
| 622ac1efb2-9d46-4073-b23b-17e9827a7961 | Translated (CM) | Criterion: | Kriterijus: |
| 632ac1efb2-9d46-4073-b23b-17e9827a7961 | Translated (90%) | Slope 0.9<404/>1.1 + intercept within < ± 1x Limit of Blank + coefficient of correlation ≥ 0.95. | Nuokrypis 0.9<404/>1.1 + sankirtos taškas < ± 1x tuščioji riba + koreliacijos koeficientas ≥ 0.95. |
| 648b30ed55-f2cb-41af-a058-dbc4d85fb367 | Translated (99%) | Stable for 7 days at 15<407/>25 °C, 14 days at 2<408/>8 °C, 6 months at <409/>20 °C. Freeze only once. | Stabilus 7 dienas 15<407/>25 °C temperatūroje, 14 dienų 2<408/>8 °C temperatūroje, 6 mėnesius <409/>20 °C temperatūroje. Galima užšaldyti tik vieną kartą. |
| 656e6bde1f-06f7-49a8-956f-7fd73c474132 | Translated (73%) | Heat-inactivated serum can be used. | Gali būti naudojamas karščiu inaktyvintas serumas. |
| 661db8da5d-c766-440d-9f77-4d89234648ff | Translated (100%) | Materials provided | Pateiktos medžiagos |
| 671d5248fa-0c6b-4b28-b45a-9d353cbe8ade | Translated (CM) | Materials required (but not provided) | Reikalingos (bet nepateikiamos) medžiagos |
| 686c79783b-59a3-4671-9071-c11bfbe66562 | Translated (0%) | <473/> 11820907322, Digoxin CalSet, 4 x 1.5 mL | <473/> 11820907322, Digoxin CalSet, 4 x 1.5 mL |
| 69a13513ec-29e4-4eba-a8ab-600d55bbee16 | Translated (100%) | <478/> 04917049190, PreciControl Cardiac II, for 2 x 2 mL each of PreciControl Cardiac II 1 and 2 | <478/> 04917049190, PreciControl Cardiac II, skirtas 2 x 2 mL kiekvienam iš PreciControl Cardiac II 1 ir 2 |
| 70e19d56a6-badb-4d37-9f4d-61a6beead91a | Translated (100%) | <483/> 11732277122, Diluent Universal, 2 x 16 mL sample diluent or | <483/> 11732277122, Diluent Universal, 2 x 16 mL mėginių skiediklis arba |
| 713f199dc5-1cc5-492a-b17d-6ffef02ec8cc | Translated (CM) | <486/> 03183971122, Diluent Universal, 2 x 36 mL sample diluent | <486/> 03183971122, Diluent Universal, 2 x 36 mL mėginių skiediklis |
| 7210469ccb-102f-4dbd-ad6c-514a6fff1aea | Translated (CM) | Assay | Tyrimas |
| 73b749146b-1d62-4255-a251-1d15d3599256 | Translated (CM) | Calibration | Kalibravimas |
| 74b0307ff6-d2e2-4628-8c22-107e957f1053 | Translated (CM) | Traceability: | Atsekamumas: |
| 75b0307ff6-d2e2-4628-8c22-107e957f1053 | Translated (81%) | This method has been standardized by weighing United States Pharmacopoeia (USP) digoxin reference material into analyte free human serum. | Šis tyrimas buvo standartizuotas pridėjus žinomą kiekį Jungtinių Valstijų Farmakopėjos (angl. United States Pharmacopoeia, USP) digoksino etaloninės medžiagos į žmogaus serumą be analitės. |
| 76b67cab85-4eab-45ea-ad98-779784fc431d | Translated (100%) | Quality control | Kokybės kontrolė |
| 772980fef1-4d7b-4a26-9930-ba5aa4142938 | Translated (CM) | For quality control, use PreciControl Cardiac II. | Kokybės kontrolei naudokite PreciControl Cardiac II. |
| 78f2e35e35-225a-4d40-ac8a-327ede63ce08 | Translated (100%) | Calculation | Skaičiavimas |
| 79cdeabab7-278a-4ee2-a92f-b59e935031ac | Translated (CM) | The analyzer automatically calculates the analyte concentration of each sample (either in nmol/L or ng/mL). | Analizatorius automatiškai apskaičiuoja kiekvieno mėginio analitės koncentraciją (nmol/L arba ng/mL). |
| 80029ee8d1-5fdc-447f-9837-ffeafba7fb78 | Translated (100%) | Conversion factors: | Perskaičiavimo daugikliai: |
| 81dd36204d-e74a-4e56-83e3-3c14b99dfd75 | Translated (CM) | nmol/L x 0.78 = ng/mL | nmol/L x 0.78 = ng/mL |
| 82a353974b-89c9-4244-8883-a1f5a4dcf653 | Translated (CM) | ng/mL x 1.28 = nmol/L | ng/mL x 1.28 = nmol/L |
| 830975f8e3-610d-467e-9b11-0655387de76e | Translated (CM) | Limitations - interference | Apribojimai - poveikiai |
| 84790d3433-f541-4492-bd94-bfd1802b542e | Translated (CM) | The assay is unaffected by icterus (bilirubin ≤ 1129 µmol/L or ≤ 66 mg/dL), hemolysis (Hb ≤ 0.621 mmol/L or ≤ 1.0 g/dL), lipemia (Intralipid ≤ 1500 mg/dL) and biotin (≤ 409 nmol/L or ≤ 100 ng/mL). | Tyrimui įtakos neturi: gelta (bilirubinas ≤1129 µmol/L arba ≤ 66 mg/dL), hemolizė (Hb ≤ 0.621 mmol/L arba ≤ 1.0 g/dL), lipemija (intralipidai ≤ 1500 mg/dL) ir biotinas (≤ 409 nmol/L arba ≤ 100 ng/mL). |
| 85a8f39629-b7c1-4c9b-869f-23fc69b6ac42 | Translated (CM) | Criterion: | Kriterijus: |
| 86a8f39629-b7c1-4c9b-869f-23fc69b6ac42 | Translated (0%) | Recovery within ± 0.08 ng/mL (± 0.10 nmol/L) for digoxin concentrations ≤ 0.8 ng/mL (≤ 1.02 nmol/L) or ± 10 % for concentrations > 0.8<786/>4.0 ng/mL (> 1.02<787/>5.12 nmol/L) or ± 12 % for concentrations > 4.0 ng/mL (> 5.12 nmol/L). | Vertės suradimas ± 0.08 ng/mL (± 0.10 nmol/L), digoksino koncentracijai esant ≤ 0.8 ng/mL (≤ 1.02 nmol/L), arba ± 10 %, koncentracijai esant > 0.8<786/>4.0 ng/mL (> 1.02<787/>5.12 nmol/L), arba ± 12 %, kai koncentracija > 4.0 ng/mL (> 5.12 nmol/L). |
| 87a3032b33-ec6a-4a3a-8fe6-76707225ec2b | Translated (100%) | No interference was observed from rheumatoid factors up to a concentration of 1630 IU/mL. | Reumatoidinio faktoriaus įtaka nebuvo pastebėta, kai jo koncentracija siekė iki 1630 IU/mL. |
| 88cf3abb78-b122-41ea-8770-27d1ee047a04 | Translated (81%) | In vitro tests were performed on a panel of commonly used pharmaceuticals. | Buvo atlikti in vitro tyrimai su grupe dažniausiai naudojamų medikamentų. |
| 89cf3abb78-b122-41ea-8770-27d1ee047a04 | Translated (0%) | While 34 of these showed no interference with the assay, uzara, nabumetone, hydrocortisone, pentoxifylline and canrenone were identified to cause falsely elevated digoxin values at concentrations of the recommended daily dose. | Nors 34 iš jų nedarė jokio poveikio tyrimui, buvo nustatyta, kad uzara, nabumetonas, hidrokortizonas, pentoksifilinas ir kanrenonas nulėmė klaidingai padidėjusias digoksino reikšmes, koncentracijai atitinkant rekomenduojamas kasdienes dozes. |
| 9032453649-2f8c-4473-998e-93ebdd8d384d | Translated (0%) | Spironolactone causes elevated digoxin results above (drug) levels of 10000 ng/mL. | Spironolaktonas nulemia padidėjusius digoksino rezultatus koncentracijai viršijant (vaisto) 10000 ng/mL. |
| 9132453649-2f8c-4473-998e-93ebdd8d384d | Translated (100%) | Canrenone causes elevated digoxin results above (drug) levels of 80000 ng/mL. | Kanrenonas nulemia padidėjusius digoksino rezultatus koncentracijai viršijant (vaisto) 80000 ng/mL. |
| 920e8881e5-7020-4e0c-8bab-e6883aba0424 | Translated (0%) | Digoxin-like immunoreactive substances (DLIS) have been identified in blood from patients in renal failure, liver failure, and pregnant women in their third trimester. | Tiriant pacientų, sergančių inkstų nepakankamumu, kepenų nepakankamumu ir nėščių moterų trečiame trimestre mėginius, buvo nustatytos į digoksiną panašios imunoreaktyvios medžiagos (angl. Digoxin-like immunoreactive substances, DLIS). |
| 930e8881e5-7020-4e0c-8bab-e6883aba0424 | Translated (0%) | Studies have shown that the presence of DLIS in a sample can result in a false elevation of digoxin when assayed by commercially available immunoassays.<Keys PW, Stafford RW. In: Taylor WJ, Finn AL, eds. Individualizing Drug Therapy: Practical Applications of Drug Monitoring. New York, Gross, Townsend, Frank, Inc; 1981; vol 3:1-21./><805>,</805><Valdes R Jr. Endogenous digoxin-like immunoreactive factors: impact on digoxin measurements and potential physiological implications. Clin Chem 1985;31(9):1525-1532./><807>,</807> | Tyrimai rodo, kad mėginyje esančios DLIS gali nulemti klaidingai padidėjusius digoksino rezultatus, kai tiriama rinkoje esančiais imunologiniais tyrimais.<Keys PW, Stafford RW. In: Taylor WJ, Finn AL, eds. Individualizing Drug Therapy: Practical Applications of Drug Monitoring. New York, Gross, Townsend, Frank, Inc; 1981; vol 3:1-21./><805>,</805><Valdes R Jr. Endogenous digoxin-like immunoreactive factors: impact on digoxin measurements and potential physiological implications. Clin Chem 1985;31(9):1525-1532./><807>,</807> |
| 94c8819f52-7a7a-4107-9f93-0eacb565cfcc | Translated (0%) | As stated by the manufacturers of digitalis antidotes, the therapeutic antibody fragments against digitalis (e.g. DigiFab<811/>, DigiBind<812/>) will interfere with digitalis immunoassay measurements. | Digitalio priešnuodžių gamintojai nurodo, kad terapiniai antikūnų fragmentai prieš digitalį (pvz.: DigiFab<811/>, DigiBind<812/>) daro poveikį digitalio imunologiniams tyrimams. |
| 95c8819f52-7a7a-4107-9f93-0eacb565cfcc | Translated (0%) | Therefore, the manufacturer of DigiFab<814/> recommends to obtain samples for determination of digoxin concentration prior to antidote administration. | Todėl DigiFab gamintojas rekomenduoja mėginius digoksino koncentracijos nustatymui paimti prieš skiriant priešnuodį. |
| 96c8819f52-7a7a-4107-9f93-0eacb565cfcc | Translated (0%) | As a consequence Elecsys Digoxin concentrations may be falsely elevated if measured in the presence of the antidote until the Fab fragments are eliminated from the body. | Elecsys Digoxin nustatyta koncentracija dėl šių priežasčių taip pat gali būti padidėjusi, jeigu matuojama mėginyje esant priešnuodžio, iki tol, kol Fab fragmentai bus pašalinti iš organizmo. |
| 9794a1d52a-69db-4bd8-9154-d4093e354e66 | Translated (100%) | Limits and ranges | Apribojimai ir reikšmių ribos |
| 98b555c182-40f7-466a-b8c0-484249d29539 | Translated (CM) | Measuring range | Matavimų ribos |
| 993ece954c-36d6-47a1-a258-203cba1a2502 | Translated (CM) | 0.2<844/>5.0 ng/mL or 0.26<845/>6.4 nmol/L (defined by the Limit of Detection and the maximum of the master curve). | 0.2<844/>5.0 ng/mL arba 0.26<845/>6.4 nmol/L (apibrėžiamos pagal nustatymo ribą ir pagrindinės kreivės maksimumą). |
| 1003ece954c-36d6-47a1-a258-203cba1a2502 | Translated (CM) | Values below the Limit of Detection are reported as < 0.2 ng/mL or < 0.26 nmol/L. | Reikšmės, esančios žemiau nustatymo ribos, yra pateikiamos kaip < 0.2 ng/mL ar < 0.26 nmol/L. |
| 1013ece954c-36d6-47a1-a258-203cba1a2502 | Translated (88%) | Values above the measuring range are reported as > 5.0 ng/mL or > 6.4 nmol/L (or up to 10.0 ng/mL or 12.8 nmol/L for 2-fold diluted samples). | Reikšmės, esančios virš matavimų ribos, yra pateikiamos, kaip > 5.0 ng/mL arba > 6.4 nmol/L (arba iki 10.0 ng/mL ar 12.8 nmol/L 2 kartus atskiestuose mėginiuose). |
| 102d0ea66f7-4c0a-401f-85b0-afdcfb1145b2 | Translated (100%) | Lower limits of measurement | Matavimo reikšmių apatinės ribos |
| 103f7d35655-7046-4b15-adf2-504f3fecac5d | Translated (CM) | Limit of Blank, Limit of Detection and Limit of Quantitation | Tuščioji riba, nustatymo riba ir kiekybinio nustatymo riba: |
| 104886d9bda-e08d-4259-85c0-58b0e28a61e5 | Translated (100%) | Limit of Blank = 0.15 ng/mL (0.19 nmol/L) | Tuščioji riba = 0.15 ng/mL (0.19 nmol/L) |
| 105638eab4f-fd04-4407-834e-e9ae0a42e672 | Translated (CM) | Limit of Detection = 0.2 ng/mL (0.26 nmol/L) | Nustatymo riba = 0.2 ng/mL (0.26 nmol/L) |
| 10643b37a66-8957-4ffc-83ba-1b6cc55d8b4d | Translated (96%) | Limit of Quantitation = 0.4 ng/mL (0.51 nmol/L) with a total allowable error of ≤ 20 % | Kiekybinio nustatymo riba = 0.4 ng/mL (0.51 nmol/L) su bendra leistina paklaida ≤ 20 % |
| 107917c779b-0522-4bd4-8ca1-a7869eab8e73 | Translated (100%) | The Limit of Quantitation is defined as the lowest amount of analyte in a sample that can be accurately quantitated with a total allowable error of ≤ 20 %. | Kiekybinio nustatymo riba yra apibrėžiama kaip mažiausias analitės kiekis mėginyje, kurį galima tiksliai nustatyti, kai bendra leidžiama paklaida yra ≤ 20 %. |
| 108af73d8a2-9877-4f90-b73e-1377ca398e21 | Translated (100%) | Dilution | Skiedimas |
| 109a05d74c7-bd38-484f-a833-bf5e52d59974 | Translated (96%) | Samples with digoxin concentrations above the measuring range can be diluted with Diluent Universal. | Mėginiai, kurių digoksino koncentracija viršija matavimų ribą, gali būti skiedžiami su Diluent Universal. |
| 110a05d74c7-bd38-484f-a833-bf5e52d59974 | Translated (100%) | The recommended dilution is 1:2 (either automatically by the MODULAR ANALYTICS E170, Elecsys 2010 or <893>cobas e</893> analyzers or manually). | Rekomenduojamas atskiedimo santykis yra 1:2 (nustatomas automatiškai MODULAR ANALYTICS E170, Elecsys 2010 arba <893>cobas e</893> analizatoriuose arba rankiniu būdu). |
| 111a05d74c7-bd38-484f-a833-bf5e52d59974 | Translated (100%) | The concentration of the diluted sample must be > 2.5 ng/mL or > 3.2 nmol/L. | Atskiesto mėginio koncentracija turi būti > 2.5 ng/mL ar > 3.2 nmol/L. |
| 11272135164-976b-4001-b26f-f185a22be77f | Translated (100%) | Expected values | Tikėtinos reikšmės |
| 113a3cf69a2-9911-4e95-8837-983b382f96f1 | Translated (0%) | The recommended therapeutic range for digoxin is 0.6<919/>1.2 ng/mL (0.77<920/>1.5 nmol/L) (ESC Guideline 2008<Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-2442./>) or even 0.5<922/>1.0 ng/mL (0.64<923/>1.3 nmol/L). | Rekomenduojamas terapinis digoksino intervalas yra 0.6<919/>1.2 ng/mL (0.77<920/>1.5 nmol/L) (EKD 2008 metų gairės<Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-2442./>) arba netgi 0.5<922/>1.0 ng/mL (0.64<923/>1.3 nmol/L). |
| 114a3cf69a2-9911-4e95-8837-983b382f96f1 | Translated (0%) | Particularly the upper end of the therapeutic range is controversial and concentrations up to 2.0 ng/mL (2.6 nmol/L) may still be applied.<Oellerich M. Pharmaka (Drug monitoring). In: Thomas L (ed.). Labor und Diagnose, TH-Books, Frankfurt, 5. edition, 1998:1174. Englisch: Clinical Laboratory. 1st English Edition 1998:1151./><926>,</926><Jortani SA, Valdes R Jr. Digoxin and Its Related Endogenous Factors. Critical Reviews Clin Lab Sci 1997;34(3):225-274./> Concentrations > 2.0 ng/mL are generally considered toxic. | Viršutinė terapinio intervalo riba yra ypač kontroversiška ir vistiek gali būti naudojamos koncentracijos iki 2.0 ng/mL (2.6 nmol/L).<Oellerich M. Pharmaka (Drug monitoring). In: Thomas L (ed.). Labor und Diagnose, TH-Books, Frankfurt, 5. edition, 1998:1174. Englisch: Clinical Laboratory. 1st English Edition 1998:1151./><926>,</926><Jortani SA, Valdes R Jr. Digoxin and Its Related Endogenous Factors. Critical Reviews Clin Lab Sci 1997;34(3):225-274./> Koncentracija > 2.0 ng/mL laikoma toksiška. |
| 115a3cf69a2-9911-4e95-8837-983b382f96f1 | Translated (0%) | Some overlap of toxic and non<929/>toxic values has been reported. | Pranešta apie toksinių ir netoksinių reikšmių persidengimą. |
| 1169a99c3d3-18f7-480c-9b6b-7a2ad5b0c006 | Translated (0%) | Therefore, clinical diagnosis should be based on clinical and laboratory data. | Todėl klinikinė diagnozė turėtų būti priimama remiantis klinikiniais ir laboratoriniais duomenimis. |
| 1179a99c3d3-18f7-480c-9b6b-7a2ad5b0c006 | Translated (100%) | Each laboratory should establish an acceptable reporting format and identify procedures for the reporting of abnormal results. | Kiekviena laboratorija turi numatyti priimtiną pranešimo formatą ir nurodyti nenormalių rezultatų pranešimo procedūras. |
| 118f1857805-4e6f-4b56-a90b-6acbba50e1b5 | Translated (100%) | Specific performance data | Specifiniai tyrimo atlikimo duomenys |
| 119cf5c9cc6-e1be-451d-9265-e5ae84be093f | Translated (CM) | Precision | Glaudumas |
| 12027d4253d-819f-4f11-a821-258cf21f11c9 | Translated (97%) | Precision was determined using Elecsys reagents, samples and controls in a protocol (EP5<966/>A3) of the CLSI (Clinical and Laboratory Standards Institute): | Glaudumas buvo nustatytas, naudojant Elecsys reagentus, mėginius ir kontrolines medžiagas, pagal CLSI (Clinical and Laboratory Standards Institute) protokolą (EP5<966/>A3): |
| 12127d4253d-819f-4f11-a821-258cf21f11c9 | Translated (100%) | 2 runs per day in duplication each for 21 days (n = 84). | 2 kartus per dieną po du tyrimus, kiekvienas tiriamas 21 dieną (n = 84). |
| 12227d4253d-819f-4f11-a821-258cf21f11c9 | Translated (100%) | The following results were obtained: | Buvo gauti šie rezultatai: |
| 123013a097f-373f-475b-936d-cb9e35080db0 | Translated (CM) | Elecsys 2010 and <975>cobas e</975> 411 analyzers | Elecsys 2010 ir <975>cobas e</975> 411 analizatoriai |
| 12442df4642-c58f-46d9-982b-4adbf74dae7b | Translated (CM) | Repeatability | Atkartojamumas |
| 1250cf4be8b-1400-462a-9768-7c709df67b5f | Translated (CM) | Intermediate precision | Tarpinis glaudumas |
| 12666902084-93c5-4702-8294-bcf89d3f1542 | Translated (CM) | Sample | Mėginys |
| 12742c3999b-b804-4b79-b5a6-3b146f251659 | Translated (CM) | Mean<999/>nmol/L | Vidurkis<999/>nmol/L |
| 1281894eebb-364c-4eaf-8d4f-ba60a93f512b | Translated (CM) | SD<1004/>nmol/L | SN<1004/>nmol/L |
| 1290d3da481-a984-4946-b535-347177a6bc05 | Translated (100%) | CV<1009/>% | CV<1009/>% |
| 1301e1a3763-5bf8-4dcb-be61-9a4a0c5e43cd | Translated (CM) | SD<1014/>nmol/L | SN<1014/>nmol/L |
| 131db5a2723-de8f-43cc-a43f-367d377e200a | Translated (100%) | CV<1019/>% | CV<1019/>% |
| 132cb6a91a2-11e9-4b17-8cb7-c205a85fe074 | Translated (CM) | Human serum 1 | Žmogaus serumas 1 |
| 1330751c964-9dbb-432f-907b-ea297627a267 | Draft (99%) | 0.724 | 0.724 |
| 134d51cd5da-7a89-4e98-a1f9-95697a8e2f16 | Draft (100%) | 0.025 | 0.025 |
| 135d504cd20-0bb8-47e0-a03c-b660aaaf1bc5 | Draft (100%) | 3.4 | 3.4 |
| 136aecff462-7d17-434b-814e-2af5066e75af | Draft (100%) | 0.046 | 0.046 |
| 13738563eda-e039-4f34-94b8-ee187be4e377 | Draft (100%) | 6.4 | 6.4 |
| 1382c237b6a-b5da-41b0-bd08-9ef987a5fb25 | Translated (100%) | Human serum 2 | Žmogaus serumas 2 |
| 139164f5bb3-bb90-482d-b7be-54597b5fe1c0 | Draft (100%) | 1.39 | 1.39 |
| 140f7eb0496-5c8d-42f0-832c-652166ca16f0 | Draft (100%) | 0.035 | 0.035 |
| 1417d1ef0eb-cda5-48db-80a3-275298979704 | Draft (100%) | 2.5 | 2.5 |
| 142ddf2c811-1ad9-4e41-b364-273f18dc4264 | Draft (100%) | 0.080 | 0.080 |
| 143a3873019-4bdd-41a4-b152-fb409300878f | Draft (100%) | 5.8 | 5.8 |
| 144d6e2d298-fa4a-4c04-a795-9d6a68ef1192 | Translated (100%) | Human serum 3 | Žmogaus serumas 3 |
| 145a0af0b99-25b0-45b0-ab1e-87c2310ad29c | Draft (100%) | 2.37 | 2.37 |
| 146b555502d-5a68-40ed-801d-37db3c247ca6 | Draft (100%) | 0.049 | 0.049 |
| 147b3d37bff-f4e8-4797-8ba9-98be47db58c6 | Draft (100%) | 2.1 | 2.1 |
| 148109bc0c8-e415-464a-a8f7-cd455d3a5501 | Draft (100%) | 0.106 | 0.106 |
| 1495587e53d-1a5e-4d0c-8ec2-398602b58f91 | Draft (100%) | 4.5 | 4.5 |
| 150fbf59e10-259a-4ed0-b113-ecd8f01e1550 | Translated (100%) | Human serum 4 | Žmogaus serumas 4 |
| 15103b1b20e-a39f-4c0a-b17a-ae97247549b3 | Draft (100%) | 3.05 | 3.05 |
| 15288119465-aec6-41bb-8df6-48faf99b042a | Draft (100%) | 0.071 | 0.071 |
| 153c146e5d8-c36b-4b8b-837c-711fa84fae28 | Draft (100%) | 2.3 | 2.3 |
| 1543ea4125d-ffcf-43c2-9e9e-f9856f906738 | Draft (100%) | 0.117 | 0.117 |
| 155a32fc761-55b0-4591-adf2-9e500eecc440 | Draft (100%) | 3.8 | 3.8 |
| 156e94522a5-e327-493c-8ab3-4bfb4ea86561 | Translated (100%) | Human serum 5 | Žmogaus serumas 5 |
| 157458d97fe-8975-4eec-9341-5544c5a1601e | Draft (100%) | 5.98 | 5.98 |
| 1580c0df380-fa88-42b9-b2c6-0fb383fbc6ea | Draft (100%) | 0.152 | 0.152 |
| 159e8f6f138-e2db-4544-8a0d-9618380246b5 | Draft (100%) | 2.5 | 2.5 |
| 160642f5574-7cf8-4a5a-961a-59994961a87d | Draft (100%) | 0.382 | 0.382 |
| 161302684db-861b-4658-817b-7f47e0e69310 | Draft (100%) | 6.4 | 6.4 |
| 162c24ee95a-677a-4542-a87d-19f6185e0af5 | Translated (0%) | PC<1158>PC = PreciControl</1158> CARDII1 | PC<1158>PC = PreciControl</1158> CARDII1 |
| 163e882b56f-dcaa-4462-babf-c3e5d8a4072c | Translated (100%) | 1.54 | 1.54 |
| 1641a1a8d81-2a1b-47c0-95a2-2e75a7831d5e | Draft (99%) | 0.045 | 0.045 |
| 165ac1ade67-3d7b-4a52-885b-14db67a21244 | Draft (100%) | 2.9 | 2.9 |
| 1660e2bf6ba-3ee1-4e6c-a7cf-5b3d7c390060 | Draft (100%) | 0.066 | 0.066 |
| 1678ba8cdbe-8855-4ab7-a98a-e479f4b264ab | Draft (100%) | 4.3 | 4.3 |
| 1687e9bbca8-f775-4d21-b981-0087919f8108 | Translated (100%) | PC CARDII2 | PC CARDII2 |
| 169329565fd-f7f6-4e99-939b-0be1fa59b31f | Translated (100%) | 3.51 | 3.51 |
| 17052adcdf0-b817-49db-ab61-4028cb4f4aff | Draft (100%) | 0.131 | 0.131 |
| 171e5034691-22d9-4042-bba4-9a8e9661e019 | Draft (100%) | 3.7 | 3.7 |
| 172fb6ff76f-d2e6-45b8-9df1-d7f3e19780bb | Draft (100%) | 0.143 | 0.143 |
| 173e561da8c-4de7-4de6-9f4f-3779c5485d4c | Draft (100%) | 4.1 | 4.1 |
| 174d6aca4b4-abf6-4aba-80b6-d966d8fa6793 | Translated (CM) | Elecsys 2010 and <1217>cobas e</1217> 411 analyzers | Elecsys 2010 ir <1217>cobas e</1217> 411 analizatoriai |
| 175ba3a0a12-c46e-4b09-a9b1-374115f5cbe3 | Translated (CM) | Repeatability | Atkartojamumas |
| 1762caebcd1-36b9-4821-8ff2-732955da2483 | Translated (CM) | Intermediate precision | Tarpinis glaudumas |
| 1771458b8ae-3da9-4e59-8cc6-ff18ef5af44d | Translated (CM) | Sample | Mėginys |
| 178f0a6453e-5e5a-4046-a3dc-4fef68c4d19f | Translated (CM) | Mean<1241/>ng/mL | Vidurkis<1241/>ng/mL |
| 1795d88246f-6a2e-4cc1-af7c-3381e6fe0c04 | Translated (CM) | SD<1246/>ng/mL | SN<1246/>ng/mL |
| 180673ff791-76bd-4bdf-985c-0fe0bcb9c2e5 | Translated (CM) | CV<1251/>% | CV<1251/>% |
| 18183f7fa0b-2e7f-4648-8dca-91357699275b | Translated (CM) | SD<1256/>ng/mL | SN<1256/>ng/mL |
| 18235343dd7-6e20-4d3a-84fd-9bc20c965ab0 | Translated (CM) | CV<1261/>% | CV<1261/>% |
| 183bd7e0213-c61b-4c7f-a5bb-9106bd2f53af | Translated (CM) | Human serum 1 | Žmogaus serumas 1 |
| 184a1f2ff88-4732-45f1-ae2c-091461644dea | Draft (100%) | 0.565 | 0.565 |
| 18550f18887-3e18-4127-9df8-dd26bf618cd8 | Draft (100%) | 0.019 | 0.019 |
| 18603505a34-5fa6-4e57-99e3-357d0d1af811 | Draft (100%) | 3.4 | 3.4 |
| 1874a78a9ee-4479-43f6-b232-ec06b7ea18b1 | Draft (100%) | 0.036 | 0.036 |
| 188250eda8b-f2a8-4cd7-a1ea-63478aa8c06d | Draft (100%) | 6.4 | 6.4 |
| 1892a3e4efc-8760-4ee1-913f-42bb9a116660 | Translated (100%) | Human serum 2 | Žmogaus serumas 2 |
| 190e255177b-8b7a-4f89-aca9-a4c9c324ff04 | Draft (100%) | 1.09 | 1.09 |
| 19128199117-6f44-4693-ace9-0a3a91ec94ad | Draft (100%) | 0.027 | 0.027 |
| 1923dbfd912-8f6b-4e6c-90fb-b5ff44dea024 | Draft (100%) | 2.5 | 2.5 |
| 19358d37312-1207-45d1-8d96-a706009211be | Draft (100%) | 0.063 | 0.063 |
| 1943e632a48-243a-43a2-aabc-8f5ef3d2ee9b | Draft (100%) | 5.8 | 5.8 |
| 1953a7230be-7cb5-4e22-90e3-a55ba33dd89a | Translated (100%) | Human serum 3 | Žmogaus serumas 3 |
| 1966d8e93a6-4390-4284-991e-af13567344fa | Draft (100%) | 1.85 | 1.85 |
| 1972e882a82-3d63-44ce-aba8-c37416a1652a | Draft (100%) | 0.039 | 0.039 |
| 1980dbb37a0-c5b1-4cee-a7d4-c9962e0b1b52 | Draft (100%) | 2.1 | 2.1 |
| 199890dab8f-3b63-4a9d-9530-080bceb5ed2b | Draft (100%) | 0.083 | 0.083 |
| 200f065fe07-1f0a-4997-a86e-2188df26588a | Draft (100%) | 4.5 | 4.5 |
| 2011da95db5-ee09-4bb4-bbc3-ce560fa6dbb2 | Translated (100%) | Human serum 4 | Žmogaus serumas 4 |
| 2028fde5dcf-ad32-4cd7-969e-1156e3af3b10 | Draft (100%) | 2.38 | 2.38 |
| 2033e77f082-a185-4571-82f4-1d247a1905f8 | Draft (100%) | 0.055 | 0.055 |
| 204030bf3d7-8f55-4da5-b8d5-027981a9f33e | Draft (100%) | 2.3 | 2.3 |
| 205c39410c6-61ed-476f-b2a3-17a81bb405a2 | Draft (100%) | 0.092 | 0.092 |
| 2068294b0f4-2a17-4551-8282-eb15a6910463 | Draft (100%) | 3.8 | 3.8 |
| 207f9c3c745-7291-4c37-b5fc-87a44ae11359 | Translated (100%) | Human serum 5 | Žmogaus serumas 5 |
| 208d91195c8-a6f7-4353-bc92-3b0563a03e66 | Draft (100%) | 4.67 | 4.67 |
| 209da148494-6b1c-480f-8089-589dc00802a3 | Draft (100%) | 0.119 | 0.119 |
| 21084eb742f-2c14-48ab-919a-3fb0fd1acbd9 | Draft (100%) | 2.5 | 2.5 |
| 2111fc4ac67-2b3e-45e8-8558-ea0cb7168aa5 | Draft (100%) | 0.299 | 0.299 |
| 2124c6b451a-fb8d-4de0-81d5-419b3633498a | Draft (100%) | 6.4 | 6.4 |
| 21387ca8988-ae74-4f14-a11e-8c8bca3c9368 | Translated (100%) | PC CARDII1 | PC CARDII1 |
| 214969cdbd8-8408-49b1-9b11-7718f1aad524 | Translated (100%) | 1.20 | 1.20 |
| 2151b80c94f-021a-47e4-85f4-9efc8a424a1d | Draft (100%) | 0.035 | 0.035 |
| 216c540bbd6-e46c-4d0b-97bd-84bebb27e975 | Draft (100%) | 2.9 | 2.9 |
| 217c95ab244-ff3e-4eb9-b811-ba55647245fe | Draft (100%) | 0.051 | 0.051 |
| 21829d9a9f4-303e-40d0-b53a-761523f971d3 | Draft (100%) | 4.3 | 4.3 |
| 219f24f0db9-3ed6-459d-812e-5898b5ae4699 | Translated (100%) | PC CARDII2 | PC CARDII2 |
| 220bb070cda-6f5e-4d8d-8248-5978d6b0e1f0 | Translated (100%) | 2.74 | 2.74 |
| 22104d787ad-2743-4ca3-bb09-79c7fad7b332 | Draft (100%) | 0.102 | 0.102 |
| 22263ba8c7a-5ded-4899-8687-1c38794059f5 | Draft (100%) | 3.7 | 3.7 |
| 2237d45232a-44aa-4852-9389-a2627ba22b68 | Draft (100%) | 0.111 | 0.111 |
| 2246aafb2c5-b7e7-44de-85ed-abb07c4aba54 | Draft (100%) | 4.1 | 4.1 |
| 225b4c0ff71-fc1a-4c9a-b356-aa7ad78f7e4c | Translated (CM) | MODULAR ANALYTICS E170, <1458>cobas e</1458> 601 and <1459>cobas e</1459> 602 analyzers | MODULAR ANALYTICS E170, <1458>cobas e</1458> 601 ir <1459>cobas e</1459> 602 analizatoriai |
| 226638c97d7-56f6-4e14-a825-8d6cae9c41f0 | Translated (CM) | Repeatability | Atkartojamumas |
| 22716c611d4-6f4f-4010-bc92-33ac177bb88b | Translated (CM) | Intermediate precision | Tarpinis glaudumas |
| 228916e3a33-903c-49e9-8b18-15794495089f | Translated (CM) | Sample | Mėginys |
| 229d33895e4-4cf8-4399-b5f5-04852df0290e | Translated (CM) | Mean<1483/>nmol/L | Vidurkis<1483/>nmol/L |
| 23064d7505c-e953-4afd-9820-15ac723dd5a6 | Translated (CM) | SD<1488/>nmol/L | SN<1488/>nmol/L |
| 231fdf5863a-b280-466d-b4f8-1f347684a4e9 | Translated (100%) | CV<1493/>% | CV<1493/>% |
| 2320e3bd1ce-abb7-4431-90e5-1456dd6644dd | Translated (CM) | SD<1498/>nmol/L | SN<1498/>nmol/L |
| 233e16b72eb-e457-409a-8708-8444a60168fa | Translated (100%) | CV<1503/>% | CV<1503/>% |
| 23402825990-acde-4b90-a58d-5b16e4d760c2 | Translated (CM) | Human serum 1 | Žmogaus serumas 1 |
| 235a31c6836-532a-47b4-bff2-cda8833d901b | Draft (100%) | 0.712 | 0.712 |
| 2360c46b06e-0e80-4977-b87d-8d3183488e0c | Draft (100%) | 0.045 | 0.045 |
| 2377088ac3c-1736-4f7e-9211-778e23192fcc | Draft (100%) | 6.3 | 6.3 |
| 238353ac69c-7ff3-414b-bb34-4e1520e9eb73 | Draft (100%) | 0.058 | 0.058 |
| 2398da95fe7-4683-4cee-97c9-bd09212ccb61 | Draft (100%) | 8.2 | 8.2 |
| 240505eb121-f274-45f1-a713-4e0574505acd | Translated (100%) | Human serum 2 | Žmogaus serumas 2 |
| 241d067caeb-af3d-47ef-aedb-cb0f181d2818 | Draft (100%) | 1.36 | 1.36 |
| 2429c3701e5-1958-4bb9-88a2-6657a2f2d9d6 | Draft (100%) | 0.038 | 0.038 |
| 243b70f7a90-ef84-4455-ba28-01af8d95887e | Draft (100%) | 2.8 | 2.8 |
| 2440ec73381-c7f8-4db7-970f-94ac14594922 | Draft (100%) | 0.058 | 0.058 |
| 245ab1edd2e-e571-43ea-baca-040cb1c1ff12 | Draft (100%) | 4.3 | 4.3 |
| 24615361c22-a61b-4b1d-8d4c-32eb746be4e7 | Translated (100%) | Human serum 3 | Žmogaus serumas 3 |
| 2470494daec-19f7-42ec-86a9-bffe488891c4 | Draft (100%) | 2.33 | 2.33 |
| 248baca79d2-3a62-42f3-8124-7dba01a15f4f | Draft (100%) | 0.058 | 0.058 |
| 2492f205cf3-b985-4f06-990b-b92c0f99af0a | Draft (100%) | 2.5 | 2.5 |
| 250429a746d-84f8-41f3-b55f-d355c027188e | Draft (100%) | 0.084 | 0.084 |
| 2513a4ddab1-7d21-4c60-b9a4-dd31cf2dd73e | Draft (100%) | 3.6 | 3.6 |
| 252dd4c73d7-7dc4-4907-82ad-30cefc966462 | Translated (100%) | Human serum 4 | Žmogaus serumas 4 |
| 2534ba24069-ea8b-47f4-8166-d613e23e8390 | Draft (100%) | 2.94 | 2.94 |
| 254966889a2-bb2d-4513-b46e-9d8ec08cede8 | Draft (100%) | 0.069 | 0.069 |
| 2552965ba90-1f79-4c71-b9bf-78a387862df0 | Draft (100%) | 2.4 | 2.4 |
| 2565d71a8e5-dcb5-4097-a3ac-19d8d7f56a89 | Draft (100%) | 0.111 | 0.111 |
| 2574cbfd39e-9b37-4889-8063-f6aa9f6b3684 | Draft (100%) | 3.8 | 3.8 |
| 25838507afc-5e48-4c2a-8f8b-8194482dfa72 | Translated (100%) | Human serum 5 | Žmogaus serumas 5 |
| 25932969738-0417-4733-ab97-b2255c90b2c8 | Draft (100%) | 5.49 | 5.49 |
| 260908301a3-a6ec-493c-ad1c-a56b187f2d9d | Draft (100%) | 0.147 | 0.147 |
| 2615c3cb9d5-7603-428a-9af9-f53e02d8308a | Draft (100%) | 2.7 | 2.7 |
| 262de8057a2-4bee-4401-897d-d6317a5a274b | Draft (100%) | 0.276 | 0.276 |
| 2633e372e41-ca24-46bc-9cdf-503acd17aed0 | Draft (100%) | 5.0 | 5.0 |
| 2645627a1b2-8ea4-46f5-94f7-9c93c97931f6 | Translated (100%) | PC CARDII1 | PC CARDII1 |
| 26528db471c-3560-498e-bf23-96e4ebce4d96 | Translated (100%) | 1.55 | 1.55 |
| 2666a38b5cd-6943-4299-9c4e-8df55043230c | Draft (100%) | 0.037 | 0.037 |
| 267da699de8-ed24-4dab-b8b4-16c2618ae870 | Draft (100%) | 2.4 | 2.4 |
| 268abf18a46-c832-4161-aa61-850dd9616336 | Draft (100%) | 0.056 | 0.056 |
| 269634d2ea0-4cd6-45a1-be86-1719471919d6 | Draft (100%) | 3.6 | 3.6 |
| 270725e1429-31b4-4705-93c7-319f3462589f | Translated (100%) | PC CARDII2 | PC CARDII2 |
| 271fceccda7-1d70-422c-ac0c-1cbb03a8c948 | Translated (100%) | 3.50 | 3.50 |
| 2728bdc0a90-263d-45a3-a638-30e8226a106b | Draft (100%) | 0.047 | 0.047 |
| 2737091c0d6-c045-4990-8fe9-d0a4a82ca1b5 | Draft (100%) | 1.3 | 1.3 |
| 2743f369bd9-bf75-4e45-bff8-d7f132256c0d | Draft (100%) | 0.082 | 0.082 |
| 27521294e07-fb5c-4a57-86ff-25fcafdef4ac | Draft (100%) | 2.3 | 2.3 |
| 276a3b062f9-82b0-4507-9502-c8826a8189f9 | Translated (CM) | MODULAR ANALYTICS E170, <1700>cobas e</1700> 601 and <1701>cobas e</1701> 602 analyzers | MODULAR ANALYTICS E170, <1700>cobas e</1700> 601 ir <1701>cobas e</1701> 602 analizatoriai |
| 277d75371ae-b1ce-45ad-b2dc-aa2bac7f4770 | Translated (CM) | Repeatability | Atkartojamumas |
| 278c2767dea-192f-4e17-87b5-f3bd2af1cc0a | Translated (CM) | Intermediate precision | Tarpinis glaudumas |
| 2793f415918-1772-4d05-8b96-a61126941ec7 | Translated (CM) | Sample | Mėginys |
| 280154b8e9f-96b4-41d3-be3b-9fffc57c11c2 | Translated (CM) | Mean<1725/>ng/mL | Vidurkis<1725/>ng/mL |
| 2812885113d-62cd-45da-88da-b95b70bdf4bf | Translated (CM) | SD<1730/>ng/mL | SN<1730/>ng/mL |
| 282e50d486d-9e93-4f62-81c3-311a0252530d | Translated (CM) | CV<1735/>% | CV<1735/>% |
| 283b2c11790-317b-45de-beb8-e5d879cde08d | Translated (CM) | SD<1740/>ng/mL | SN<1740/>ng/mL |
| 2849475fd2f-ff71-4389-893f-2d049f3dcd5b | Translated (CM) | CV<1745/>% | CV<1745/>% |
| 28510da67f4-c79b-485d-b9d4-d968c272db46 | Translated (CM) | Human serum 1 | Žmogaus serumas 1 |
| 28682d933bb-3229-4207-9c8c-53f6ab39da6c | Draft (100%) | 0.556 | 0.556 |
| 287b8b76bf8-4e42-4ec7-91af-5e2ed98e28bc | Draft (100%) | 0.035 | 0.035 |
| 288fad0e7c5-6a25-4b6a-bf85-0a498c83da8f | Draft (100%) | 6.3 | 6.3 |
| 289a53d5f02-a19c-4f96-844e-8bb0ef10d802 | Draft (100%) | 0.046 | 0.046 |
| 290a8b98bcf-48e6-43ae-b6fc-60c71747eb4a | Draft (100%) | 8.2 | 8.2 |
| 291c6aeb0c9-f2d1-4037-bd18-dc3b5e0949f2 | Translated (100%) | Human serum 2 | Žmogaus serumas 2 |
| 292a70fbcff-80c7-4a16-b085-f2361d7c810d | Draft (100%) | 1.07 | 1.07 |
| 293fea6a729-27f6-48f5-9430-d9c0e3aef35c | Draft (100%) | 0.030 | 0.030 |
| 2945b0b7ad2-d734-42db-9094-d37765ceffca | Draft (100%) | 2.8 | 2.8 |
| 2951b6ad031-54c6-4b8c-af0d-6393281e6515 | Draft (100%) | 0.045 | 0.045 |
| 2961dd99558-9fb1-4f53-aad4-eaf1ac371c4c | Draft (100%) | 4.3 | 4.3 |
| 297d87c0a91-2157-4661-9c66-cf665fa90bf6 | Translated (100%) | Human serum 3 | Žmogaus serumas 3 |
| 2987063449e-5404-4cda-909f-6f5541efddd1 | Draft (100%) | 1.82 | 1.82 |
| 2997eab39ff-c246-430c-b3bc-3b3a830a9617 | Draft (100%) | 0.045 | 0.045 |
| 300525c63f8-a8cf-4cd1-9363-dcb5b38855bf | Draft (100%) | 2.5 | 2.5 |
| 301dd2ea8e7-e36d-4e84-b21d-cf12d9ad05e3 | Draft (100%) | 0.066 | 0.066 |
| 302e6433e9f-360c-408e-bf8f-a1b9e8b491b2 | Draft (100%) | 3.6 | 3.6 |
| 3032def9b7d-a354-464b-b30a-0e1854730556 | Translated (100%) | Human serum 4 | Žmogaus serumas 4 |
| 30472552d3c-1a45-4fd6-9909-f58d79413b0c | Draft (100%) | 2.29 | 2.29 |
| 30508c30587-b843-43a3-b972-fcf8b71fe2df | Draft (100%) | 0.054 | 0.054 |
| 3065dd27881-7a0f-4dcd-8093-aef93f34d5b9 | Draft (100%) | 2.4 | 2.4 |
| 3079997d4d5-c186-41d3-916b-7d6415b51b0e | Draft (100%) | 0.087 | 0.087 |
| 308899d97c5-83f3-44e0-812d-8e213388300d | Draft (100%) | 3.8 | 3.8 |
| 309dad00c3f-35d2-406e-8026-b3cd0c4584b9 | Translated (100%) | Human serum 5 | Žmogaus serumas 5 |
| 3105aa247b0-ce3d-4ab9-8c48-646b49f93d1a | Draft (100%) | 4.29 | 4.29 |
| 311bca6230b-adc8-4d9b-be9a-07e473d32c83 | Draft (100%) | 0.115 | 0.115 |
| 312e4c7aeef-1822-45b4-b0bb-fa6b06f9ed7f | Draft (100%) | 2.7 | 2.7 |
| 31381103ef8-bbbe-45eb-beb2-16d5a667df34 | Draft (100%) | 0.216 | 0.216 |
| 3149131616f-8741-4077-85db-821797dd693b | Draft (100%) | 5.0 | 5.0 |
| 3153228ea51-f15b-450c-9999-55049861b950 | Translated (100%) | PC CARDII1 | PC CARDII1 |
| 3160aaa06d1-c605-447b-b84d-88473dbe96f2 | Translated (100%) | 1.21 | 1.21 |
| 31746f704a5-490a-4004-bae3-1da47c3bbe71 | Draft (100%) | 0.029 | 0.029 |
| 3188cb029e4-ce12-4588-ac1f-fe5eed5ffed8 | Draft (100%) | 2.4 | 2.4 |
| 319ac28ee4f-4ba6-45c0-b43b-4e84b45de28c | Draft (100%) | 0.044 | 0.044 |
| 3205b4538d4-2bb1-46ce-b848-973db7575cfb | Draft (100%) | 3.6 | 3.6 |
| 3210a28bf4a-76ec-4c7a-8bd0-0b917caa634e | Translated (100%) | PC CARDII2 | PC CARDII2 |
| 322d65fbb2a-2d5e-42a1-97ff-2169c7651175 | Translated (100%) | 2.74 | 2.74 |
| 323ac65995c-3ec0-4974-b2e8-959f72c855c5 | Draft (100%) | 0.037 | 0.037 |
| 3248e944d53-654f-4215-b04d-0215b95dba48 | Draft (100%) | 1.3 | 1.3 |
| 325c3c2c2c7-6254-4281-a488-5adbc4ae3a3d | Draft (100%) | 0.064 | 0.064 |
| 326f85d062f-dc4e-4c7f-a49d-20c4d56caf56 | Draft (100%) | 2.3 | 2.3 |
| 327d634f0ab-4ef1-4d91-b6f9-ee840f73ae85 | Translated (CM) | Analytical specificity | Analitinis specifiškumas |
| 328720128ab-b41f-4c1c-af35-c43d9ea9e41e | Translated (0%) | For the Co-analytes tested, the following relative Co-analyte reactivities were found: | Ištyrus koanalites nustatytas toks santykinis reaktyvumas su koanalitėmis: |
| 329476b3954-5ef6-4eb4-8639-6bbf7354ec64 | Translated (0%) | Co-analyte | Koanalitė |
| 3309fb32eff-e9a9-4043-8784-f513b47677cd | Translated (0%) | Concentration<1956/>ED50<1957/>ng/mL | Koncentracija<1956/>ED50<1957/>ng/mL |
| 33131f2e9fd-56fe-41ef-85a7-7ef6132c77f1 | Translated (0%) | Relative Co-analyte reactivity <1963/>% | Santykinis reaktyvumas su koanalitėmis <1963/>% |
| 332cc95258c-96a4-4fb4-bb23-74621544c128 | Translated (0%) | α-acetyldigoxin | α-Acetildigoksinas |
| 33373ce54d3-478e-4a3e-91aa-95071fa212ba | Translated (100%) | 1.18 | 1.18 |
| 33493d463ee-cafa-4542-9555-e69838789250 | Translated (99%) | 77.9 | 77.9 |
| 33511f03bc1-f228-41fe-b04d-d1e454a8b952 | Draft (90%) | β-acetyldigoxin | β-Acetildigoksinas |
| 33655461531-2e29-4b41-8a21-dd0ab46324ba | Translated (100%) | 1.09 | 1.09 |
| 33701fc8e14-d263-4e9b-894b-dd75ff219e36 | Draft (100%) | 84.4 | 84.4 |
| 338e73a72d6-7d7a-418b-b4a0-c6d3a25ecb0a | Translated (90%) | β-methyldigoxin | β-Metildigoksinas |
| 339f7bde1b6-810b-4260-a757-213a1181ab83 | Translated (100%) | 1.05 | 1.05 |
| 340ddae5eea-6088-4d48-a1c8-e3ed6a5ab8a2 | Translated (99%) | 87.9 | 87.9 |
| 341f28f939a-4742-456d-b89d-db6bbbfe02d5 | Translated (0%) | Lanatoside C | Lanatozidas C |
| 342d562432f-1e5c-4418-b41e-f7da0bf294d0 | Translated (100%) | 1.31 | 1.31 |
| 343795f6fda-602a-4b89-9c25-569a9f0fa85a | Draft (99%) | 65.2 | 65.2 |
| 3445b95c51c-0c96-4490-ac7a-82eb94df2f84 | Translated (0%) | Deslanoside | Deslanozidas |
| 34522de9870-f19b-4c60-923a-395332580de5 | Translated (100%) | 1.08 | 1.08 |
| 346e5b76778-55cb-48e8-8a7f-5c4fc5cc8bf3 | Draft (100%) | 85.6 | 85.6 |
| 3475d0e92a8-86cf-42e2-9489-15a3c8263c71 | Translated (0%) | Digoxigenin-bis-digitoxoside | Digoksigenin-bis-digitoksozidas |
| 34836980153-a94c-402d-9282-a3b92c22fd18 | Translated (100%) | 0.853 | 0.853 |
| 349a7f396eb-67c7-4854-8879-2d258fc1df4f | Draft (100%) | 108 | 108 |
| 3507602b490-adad-46fb-bca3-1f72ad0729fd | Translated (0%) | Digoxigenin-mono-digitoxoside | Digoksigenin-mono-digitoksozidas |
| 351b525b59c-ef4f-4a51-a4c1-0b353a554a4a | Translated (100%) | 0.603 | 0.603 |
| 3521e1e3cf8-241d-446f-bd2e-95c49487e2dc | Translated (99%) | 141 | 141 |
| 3537802b882-a037-4e81-9411-d262d3e66244 | Translated (79%) | For the substances tested, the following cross-reactivities were found: | Su tirtomis medžiagomis buvo gautos tokios kryžminės reakcijos: |
| 354a06e5959-8339-4318-9189-bf04d31777e4 | Translated (100%) | Substances | Medžiagos |
| 355cb06f4b7-9e2d-424f-bd40-a968e23217b5 | Translated (0%) | Concentration tested<2084/>ng/mL | Tirta koncentracija<2084/>ng/mL |
| 356991d27ad-aa9d-4ad8-8972-84f54ffd80ef | Translated (96%) | Cross-reactivity <2090/>% | Kryžminis reaktyvumas<2090/> % |
| 357c0973546-6747-4a2b-af69-459e0ccaf314 | Translated (100%) | Digitoxin | Digitoksinas |
| 3580d245a76-1584-4da2-b210-5eadc4841cae | Translated (100%) | 250 | 250 |
| 3596ac53b37-ee83-44d7-bf17-724c742a0dc0 | Draft (99%) | 0.522 | 0.522 |
| 36098f60c9b-deb9-4186-8a90-1015b22c6667 | Translated (CM) | Digitoxigenin | Digitoksigeninas |
| 3619a80088c-e837-4ab9-8382-56de150b457a | Translated (100%) | 250 | 250 |
| 3626049a7bc-fc95-4b63-a3a7-0d66e0f01dd1 | Draft (100%) | 0.529 | 0.529 |
| 363f614a740-1535-4fc7-82d6-82180ad98a75 | Translated (CM) | Digoxigenin | Digoksigeninas |
| 3643b9a0afe-3c51-4708-8c5f-fa3586bf13c0 | Translated (100%) | 6.00 | 6.00 |
| 365039150af-aa13-4d0b-983d-adb7e5abdbbf | Draft (100%) | 31.3 | 31.3 |
| 3668c6952d3-a616-41f1-b2e9-00b2f3f04d49 | Translated (CM) | Dihydrodigoxin | Dihidrodigoksinas |
| 367cf625a66-55f7-419a-8a24-734e59d14e40 | Translated (100%) | 1000 | 1000 |
| 368ab8f0d57-48df-45c1-b7a0-172edb731f98 | Draft (100%) | 0.201 | 0.201 |
| 369dbd9a883-29a6-4ead-9371-29c79e5761db | Translated (0%) | K-strophanthine | K-strofantinas |
| 37042927b08-5436-4c0a-9c20-452418434bf0 | Translated (100%) | 1250 | 1250 |
| 3714351e49f-8304-4e0a-9303-e03454883565 | Translated (99%) | 0.137 | 0.137 |
| 372d86e6de5-0c96-4d64-999b-7e178b95ea9c | Translated (0%) | No significant cross-reactivity (< 0.01 %) was found for the following substances (tested concentration 5000 ng/mL): | Nebuvo nustatyta jokio kryžminio reaktyvumo (< 0.01 %) su šiomis medžiagomis (tirta koncentracija - 5000 ng/mL): |
| 3734645ea37-d7e9-4882-a7fd-a2f8c125d856 | Translated (0%) | Cortisol, prednisone, β<2172/>estradiol, d<2173/>aldosterone, DHEA, dexamethasone, furosemide, sulthiame, quinidine (free base) and oleandrin. | Kortizolis, prednizonas, β<2172/>estradiolis, d<2173/>aldosteronas, DHEA, deksametazonas, furozemidas, sultiamas, chinidinas (laisva bazė) ir oleandrinas. |
| 3744645ea37-d7e9-4882-a7fd-a2f8c125d856 | Translated (0%) | For testosterone and ouabain a cross-reactivity of < 0.1 % was found at 5000 ng/mL. | Tiriant testosteroną ir ouabainą buvo nustatytas < 0.1 % kryžminis reaktyvumas koncentracijai esant 5000 ng/mL. |
| 3754645ea37-d7e9-4882-a7fd-a2f8c125d856 | Translated (83%) | For progesterone a cross-reactivity of < 0.05 % was found at 5000 ng/mL. | Tiriant progesteroną buvo nustatytas 0.05 % kryžminis reaktyvumas koncentracijai esant 5000 ng/mL. |
| 376087b055a-36df-48ff-a676-f50a6d734e2c | Translated (100%) | References | Nuorodos |